IMI2 - Call 13
IMI2 – Call 13 was launched on 30 November 2017 with the following topics:
- Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
- Genome-environment interactions in inflammatory skin disease
- The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
- Mitochondrial dysfunction in neurodegeneration
- Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative
- A sustainable European induced pluripotent stem cell platform
- Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
- Human tumour microenvironment immunoprofiling
- ConcePTION – Continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
- Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
- Translational safety biomarker pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
- Pilot programme on a clinical compound bank for repurposing: cardiovascular diseases and diabetes
- Pilot programme on a clinical compound bank for repurposing: respiratory diseases
- Pilot programme on a clinical compound bank for repurposing: neurodegenerative diseases
- Pilot programme on a clinical compound bank for repurposing: rare/orphan diseases
More information on the topics can be found in IMI’s press release and in the Call text. Other relevant documents can be found on the IMI2 Call documents page.
Projects
The projects resulting from IMI2 – Call 13 are:
- MOBILISE-D - Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement
factsheet | website - IMMUCAN - Integrated immunoprofiling of large adaptive cancer patients cohorts
factsheet | website - CONCEPTION - Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation
factsheet | website - TransBioLine - Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
factsheet | website - BIOMAP - Biomarkers in atopic dermatitis and psoriasis
factsheet | website - VALUE-Dx - The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
factsheet | website - CARDIATEAM - Cardiomyopathy in type 2 diabetes mellitus
factsheet | website - NeuroDeRisk - Neurotoxicity de-risking in preclinical drug discovery
factsheet | website - EBiSC2 – A sustainable European bank for induced pluripotent stem cells
factsheet | website - PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease
factsheet | website - NEURONET - Efficiently networking European neurodegeneration research
factsheet | website - STOPFOP - Saracatinib trial to prevent FOP
factsheet | STOPFOP - PD-MIND - Parkinson disease with mild cognition impairment treated with nicotinic agonist drug
factsheet | website
Call statistics
- Proposals submitted: 38
- Inadmissible & ineligible proposals: 2
- Proposals recommended for funding: 13
- Proposals not recommended for funding: 23